Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab + paclitaxel vs paclitaxel + placebo in first-line HER2-negative metastatic breast cancer
jRCT2080221950Phase 3Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Oct 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing Bevacizumab + paclitaxel with Placebo + paclitaxel (2 arms). Primary endpoint: Progression-free survival. Started Oct 2012; status: completed.
02
Drugs
bevacizumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCT2080221950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221950.